Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?
- Department of Immunotechnology
Monoclonal antibodies have many potential therapeutic benefits. However, when applied to humans, mouse monoclonal antibodies have several disadvantages. Here Carl Borrebaeck and colleagues describe a strategy to overcome the anti-Gal activity, thought to be one of the reasons why mouse mAbs have a limited half-life. © 1993.
- ISSN: 0167-5699